GlassScriptPhysician profile
Emad Sedki
NPI 1649446766
$21,503.18
in general payments reported to CMS, 2019-2025
41 companies · $8,350 in 2025
The $8,350 reported for 2025 was more than what 95% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,086 · 2020: $1,076 · 2021: $1,132 · 2022: $533 · 2023: $1,097 · 2024: $8,229 · 2025: $8,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $4,456 · Education: $83.15 · Travel and Lodging: $16.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,120.00 |
| Food and Beverage | $4,455.82 |
| Education | $83.15 |
| Travel and Lodging | $16.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $14,382.44 | 2020-2025 | Terlivaz, Acthar |
| Astrazeneca Pharmaceuticals LP | $1,013.35 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $672.12 | 2019-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $641.67 | 2019-2024 | Korsuva, Veltassa |
| Opko Pharmaceuticals, LLC | $611.48 | 2019-2025 | Rayaldee |
| Horizon Therapeutics Plc | $502.93 | 2019-2023 | Krystexxa |
| Amgen INC. | $429.91 | 2023-2025 | Krystexxa, Tavneos, Parsabiv |
| Alexion Pharmaceuticals, INC. | $310.31 | 2022-2025 | Ultomiris |
| Novo Nordisk INC | $282.44 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Ani Pharmaceuticals, INC. | $249.35 | 2022-2024 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $190.50 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $183.95 | 2023-2025 | |
| Recor Medical INC | $153.78 | 2025 | Paradise Ultrasound Renal Denervation System |
| Bayer Healthcare Pharmaceuticals INC. | $150.41 | 2022-2024 | |
| Fresenius USA Marketing, INC. | $148.05 | 2019-2024 | Velphoro |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emad Sedki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.